Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars

Celltrion’s CT-P47 Phase III Clinical Trial Demonstrates Equivalence with Actemra®/Roactemra® (tocilizumab)

Dec 14, 2023

Celltrion revealed in a corporate filing with the Repository of Korea’s Corporate Filings (DART) that its phase III clinical trial of CT-P47, biosimilar to Genentech’s Actemra®/Roactemra® (tocilizumab), demonstrated equivalence with the originator product in patients with rheumatoid arthritis.  Celltrion confirmed it intends to apply for approval for all indications that Actemra®/Roactemra® is approved for.  On 31 May 2023 Celltrion released its phase I data for CT-P47.